Updates
Dr Grace Nabakooza: Creating accessible products that prevent disease and improve life.
How would you describe yourself I am Grace Nabakooza, professionally, I am passionate about global health security, with a focus ...
Dr Prossy Namuwulya: Translating research into practical applications that benefit society.
How would you describe yourself? Prossy Namuwulya is a distinguished research laboratory scientist at the Uganda Virus Research Institute in ...
Understanding the genetics of the Measles and Measles-like diseases in the Ugandan population
Prossy Namuwulya has worked with the Uganda Virus Research Institute (UVRI) as a Molecular Biologist for close to 15 years. ...
Latest Projects
The Entebbe Mother and Baby Study (EMaBS) began as a trial [ISRCTN32849447] aimed at investigating the potential benefits of treating worm infections during pregnancy and early childhood. Today, this cohort has evolved into a unique platform for understanding how early life exposures influence health outcomes in tropical settings.
NIHR Global Health Research Group on Vaccines for Vulnerable people in Africa (VAnguard)
WORMVACS2.0 will establish an effective pipeline for helminth vaccine development focusing on schistosomes and hookworms, to support control and elimination of some of the world’s most devastating and persistent Neglected Tropical Diseases (NTDs).
WORMVACS2.0 is funded by Horizon Europe and will run between September 2023 and August 2028.
The Uganda Schistosomiasis Multidisciplinary Research Center (U-SMRC) has been established to build expertise and understanding of the underlying biological determinants of severe schistosomal morbidity and to develop and identify appropriate interventions for prevention and management of this important disease.